Bray E P, Jones M I, Banting M, Greenfield S, Hobbs F D R, Little P, Williams B, Mcmanus R J
School of Psychology, University of Central Lancashire, Preston, UK.
Primary Care Clinical Sciences, University of Birmingham, Edgbaston, UK.
J Hum Hypertens. 2015 Jul;29(7):436-41. doi: 10.1038/jhh.2014.108. Epub 2015 Jan 8.
This study aimed to evaluate, in detail, the implementation of the self-management intervention used in the TASMINH2 trial. The intervention, comprising self-monitoring for the first week of each month and an individualised treatment self-titration schedule, was developed from a previous trial of self-management. Two hundred and sixty-three patients with poorly controlled but treated hypertension were randomised to receive this intervention and underwent training over two or three sessions. Participants were followed up for 12 months during which time process data were collected regarding the persistence and fidelity of actual behaviour compared with intervention recommendations. Two hundred and forty-one (92%) patients completed training of whom 188 (72%) self-managed their BP and completed at least 90% of expected self-monitoring measurements for the full year of the study. Overall, 268/483 (55%) of recommended medication changes were implemented. Only 25 (13%) patients had controlled BP throughout the year and so were not recommended any medication changes. Adherence to the protocol reduced over time as the number of potential changes increased. Of those self-managing throughout, 131 (70%) made at least one medication change, with 77 (41%) implementing all their recommended changes. In conclusion, self-management of hypertension was possible in practice with most participants making at least one medication change. Although adherence to the intervention reduced over time, implementation of treatment recommendations appeared better than equivalent trials using physician titration. Future self-management interventions should aim to better support patients' decision making, perhaps through enhanced use of technology.
本研究旨在详细评估TASMINH2试验中使用的自我管理干预措施的实施情况。该干预措施包括每月第一周的自我监测以及个性化治疗自我滴定方案,是在先前的自我管理试验基础上制定的。263例血压控制不佳但接受治疗的高血压患者被随机分组接受该干预措施,并接受了两到三次培训课程。对参与者进行了12个月的随访,在此期间收集了与干预建议相比实际行为的持续性和保真度的过程数据。241例(92%)患者完成了培训,其中188例(72%)对血压进行了自我管理,并在研究的一整年中完成了至少90%的预期自我监测测量。总体而言,268/483(55%)的推荐药物调整得以实施。只有25例(13%)患者全年血压得到控制,因此未被建议进行任何药物调整。随着潜在调整数量的增加,对方案的依从性随时间下降。在全程进行自我管理的患者中,131例(70%)至少进行了一次药物调整,其中77例(41%)实施了所有推荐的调整。总之,在实践中高血压自我管理是可行的,大多数参与者至少进行了一次药物调整。尽管随着时间推移对干预措施的依从性降低,但治疗建议的实施情况似乎优于使用医生滴定的等效试验。未来的自我管理干预措施应旨在更好地支持患者的决策,或许可以通过加强技术应用来实现。